1. The Prognostic Value of UHRF-1 and p53 in Gastric Cancer.
- Author
-
Babacan, Nalan A., Eğilmez, Hatice Reyhan, Yücel, Birsen, Parlak, Ilknur, Şeker, Mehmet Metin, Kaçan, Turgut, Bahçeci, Aykut, Cihan, Sener, Akinci, Bülent, Eriten, Berna, and Kılıçkap, Saadettin
- Subjects
PROTEIN metabolism ,STOMACH tumors ,CANCER patients ,GASTRITIS ,GENE expression ,IMMUNOHISTOCHEMISTRY ,SURVIVAL analysis (Biometry) ,TUMOR markers ,DESCRIPTIVE statistics ,PROGNOSIS - Abstract
Background/Aims: This study aimed to examine whether UHRF-1 and p53 overexpression is a prognostic marker for gastric cancer. Patients and Methods: Sixty-four patients with gastric cancer (study group) and 23 patients with gastritis (control group) were evaluated. Immunohistochemistry was used to examine expression of UHRF-1 and p53 in gastric cancers and a control group diagnosed with gastritis. Results: The median age was 63 years (18-83 years) in the study group. UHRF-1 was positive in 15 (23%) patients with gastric cancer and five (21.7%) patients with gastritis (P = 0.559). UHRF1 expression level in gastric cancer is more powerful than in gastritis (P = 0.046). Thirty-seven (61%) patients with gastric cancer and only one patient with gastritis were p53 positive (P < 0.001). After a median follow-up of 12 months (1-110), the 2-year overall survival rates were 55% and 30% in negative and positive p53, respectively (P = 0.084). Also, the 2-year overall survival rates were 45% and 53% in negative and positive UHRF-1, respectively (P = 0.132). Conclusion: According to this study, UHRF-1 and p53 were not prognostic factors for gastric cancer, whereas they may have a diagnostic value for differentiating between gastric cancer and gastritis. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF